Key Highlights

  • The stock rose USD 0.4599, or 15.33%, to USD 3.46 in regular trading on November 3, 2026.
  • Cash and short-term investments were USD 53.4 million at June 30, 2026, up from USD 6.1 million at December 31, 2025.
  • The PRECISE-AD Phase 1b study enrolled 144 participants, and 12-month topline data are expected in the first quarter of 2027.
  • Second quarter 2026 net loss was USD 11.7 million, or USD 1.28 per share, versus USD 10.1 million a year earlier.
  • Blinded interim data showed no ARIA-E cases, with total ARIA at 4.4%, all mild and asymptomatic.

What Moved ProMIS Shares Today (up USD 0.4599, 15.33%)

ProMIS Neurosciences (NASDAQ:PMN) rose 15.33% to USD 3.46 in regular trading on November 3, 2026, up USD 0.4599 from the November 2 close of about USD 3.00 (calculated). The screen showed Volume of about 244.13K shares and a Market Capitalisation of about USD 31.03 million.

No company press release or regulatory filing dated October 30 to November 3, 2026 was identified as the cause. The advance may reflect momentum ahead of a data event rather than a fresh announcement. At under USD 5 the shares are a penny stock, with the volatility, thin Liquidity and dilution risk that implies.

What Did the Latest Update Show?

ProMIS is a clinical-stage biotechnology company developing antibodies against toxic misfolded proteins in neurodegenerative disease. Its lead candidate, PMN310, targets toxic amyloid Beta oligomers in early Alzheimer's disease.

In its August 13, 2026 update, the company said PRECISE-AD completed enrollment in December 2025 with 144 subjects at 22 U.S. sites.

As of a July 22, 2026 data cutoff, 136 of the 144 were evaluable, all had been dosed for at least six months, 78% for nine months and 49% had completed 12 months. The trial remains blinded.

What Do the Interim Safety and Biomarker Figures Say?

The company reported no ARIA-E cases. Total ARIA was 4.4%, all mild, asymptomatic and limited to microhemorrhages. No treatment-related serious adverse events or drug-related discontinuations were reported.

Pooled and blinded biomarker data showed plasma pTau217 down about 15% from baseline through Day 169 and cerebrospinal fluid MTBR-tau243 down about 13.3%. Because the data are pooled across drug and placebo, they do not show the effect of PMN310 itself, and the unblinded 12-month cognitive results are the real test. All patients are expected to complete 12 months of dosing by the fourth quarter of 2026.

Separately, Dr. Ivana Rubino became Chief Commercial Officer effective October 5, 2026.

How Are Finances and Dilution Risk?

For the second quarter of 2026, net loss was USD 11.7 million, or USD 1.28 per share, against USD 10.1 million, or USD 7.26 per share, in the second quarter of 2025. Research and Development expense was USD 9.5 million, up from USD 8.7 million.

Cash and short-term investments of USD 53.4 million reflect about USD 70.1 million in net proceeds from a January 2026 private placement, which was announced as up to about USD 175 million including warrants. The company said resources should fund planned operations through 2027, beyond the expected readout. Warrant exercises or a new raise could still add shares, and a negative readout would weigh on funding options.

What Should Readers Watch Next?

The third quarter 2026 financial report should update cash and spending. The company plans to present at the CTAD conference.

The major event is the unblinded 12-month topline readout in the first quarter of 2027, after database lock and statistical analysis. Until then, any move in the shares is more likely to reflect trading sentiment than confirmed efficacy results.